Salem Investment Counselors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Salem Investment Counselors’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-55	Closed	-$988	–	441
2026 Q2	$988	Hold	55	–	–	﹤0.01%	1155
2026 Q1	$765	Buy	+55	New	+$774	﹤0.01%	1147
2025 Q4	–	Sell	-55	Closed	-$748	–	421
2025 Q3	$748	Hold	55	–	–	﹤0.01%	1142
2025 Q2	$353	Hold	55	–	–	﹤0.01%	1128
2025 Q1	$195	Hold	55	–	–	﹤0.01%	1183
2024 Q4	$208	Hold	55	–	–	﹤0.01%	1158
2024 Q3	$179	Hold	55	–	–	﹤0.01%	1166
2024 Q2	$105	Hold	55	–	–	﹤0.01%	1145
2024 Q1	$157	Hold	55	–	–	﹤0.01%	1147
2023 Q4	$810	Buy	+55	New	+$843	﹤0.01%	1035

Other funds holding AMLX

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

PPWP

Premier Path Wealth Partners Madison, New Jersey $856M AUM 23.55% 1-Year Est. Return

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

VSQM

V-Square Quantitative Management Chicago, Illinois $1.09B AUM 23.97% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

CAIM

Catherine Avery Investment Management Longboat Key, Florida $116M AUM 31.75% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Salem Investment Counselors's AMLX Position: Q3 2026 in Review

Salem Investment Counselors sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2026, closing a stake of 55 shares — an estimated $988 sold.

Salem Investment Counselors first reported a position in AMLX in Q4 2023 and held it in 10 quarters. The position peaked at $988 in Q2 2026. 12 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

Salem Investment Counselors reported no remaining Amylyx Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
Salem Investment Counselors sold 55 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $988.
Salem Investment Counselors first reported a position in Amylyx Pharmaceuticals in Q4 2023 and held it in 10 quarters.
Salem Investment Counselors's Amylyx Pharmaceuticals position peaked at $988 in Q2 2026.
12 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on Salem Investment Counselors's 13F filing for Q3 2026, filed 13 Oct 2026.